Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Top Stocks 2021: If You Only Buy One Battery Stock, It Better Be MP Materials

For investors betting on improvements in battery technology, my top pick right now is MP stock s the long-term winner in this race.

Vaccitech IPO: When Does Vaccitech Go Public? What Is the VACC Stock IPO Price Range?

The upcoming Vaccitech IPO is one I think investors will have their eye on, as speculators look for early stage biopharma plays today.

ADMA Stock: The Big FDA News Boosting ADMA Biologics Today

Today, ADMA stock is a big mover as the company announced a very bullish FDA approval allowing the company to scale its core product.

CLOV Stock: Short Squeeze Hopes Power Clover Health 16% Higher

Today, CLOV stock is on the move in a big way as speculators have bid this stock up on heavy volume in anticipation of a short squeeze.

7 Marijuana Stocks to Buy As Canada’s Consumption Continues to Rise

Looking for cannabis exposure? These seven weed stocks based in Canada could provide some explosive growth to portfolios over time.